DSpace Repository

Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC

Show simple item record

dc.contributor Universitat de Vic. Càtedra de la Sida i Malalties Relacionades
dc.contributor.author Santos, José R.
dc.contributor.author Saumoy, M.
dc.contributor.author Curran, Adrian
dc.contributor.author Bravo, Isabel
dc.contributor.author Navarro, Jordi
dc.contributor.author Estany, Carla
dc.contributor.author Podzamczer Palter, Daniel
dc.contributor.author Ribera, Esteban
dc.contributor.author Negredo, Eugenia
dc.contributor.author Clotet, Bonaventura
dc.contributor.author Paredes, Roger
dc.date.accessioned 2015-01-05T10:42:32Z
dc.date.available 2015-01-05T10:42:32Z
dc.date.created 2014
dc.date.issued 2014
dc.identifier.citation Ramon Santos, J., Saumoy, M., Curran, A., Bravo, I., Navarro, J., Estany, C., et al. (2014). Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC. Journal of the International Aids Society, 17, 42-42. ca_ES
dc.identifier.issn 1758-2652
dc.identifier.uri http://hdl.handle.net/10854/3793
dc.description.abstract Abstract INTRODUCTION: Previous studies have described improvements on lipid parameters when switching from other antiretroviral drugs to tenofovir (TDF) and impairments in lipid profile when discontinuing TDF. [1-3] It is unknown, however, if TDF has an intrinsic lipid-lowering effect or such findings are due to the addition or removal of other offending agents or other reasons. MATERIALS AND METHODS: RESULTS: 46 subjects with a median age of 43 (40-48) years were enrolled in the study: 70% were male, 56% received DRV/r and 44% LPV/r. One subject withdrew the study voluntarily at week 4 and another one interrupted due to diarrhoea at week 24. Treatment with TDF/FTC decreased total, LDL and HDL-cholesterol from 235.9 to 204.9 (p<0.001), 154.7 to 127.6 (p<0.001) and 50.3 to 44.5 mg/dL (p<0.001), respectively. In comparison, total, LDL and HDL-cholesterol levels remained stable during placebo exposure. Week 12 total cholesterol (p<0.001), LDL-cholesterol (p<0.001) and HDL-cholesterol (p=0.011) levels were significantly lower in TDF/FTC versus placebo. Treatment with TDF/FTC reduced the fraction of subjects with abnormal fasting total-cholesterol (≥200 mg/dL) from 86.7% to 56.8% (p=0.001) and LDL-cholesterol (≥130 mg/dL) from 87.8% to 43.9% (p<0.001), which was not observed with placebo. There were no virological failures, and CD4 and triglyceride levels remained stable regardless of exposure. CONCLUSION: Coformulated TDF/FTC has an intrinsic lipid-lowering effect, likely attributable to TDF. ca_ES
dc.format application/pdf
dc.format.extent 1 p, ca_ES
dc.language.iso eng ca_ES
dc.publisher International AIDS Society ca_ES
dc.rights Aquest document està subjecte a aquesta llicència Creative Commons ca_ES
dc.rights.uri http://creativecommons.org/licenses/by/3.0/es/ ca_ES
dc.subject.other Sida -- Tractament ca_ES
dc.title Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC ca_ES
dc.type info:eu-repo/semantics/article ca_ES
dc.identifier.doi https://doi.org/10.7448/IAS.17.4.19550
dc.rights.accesRights info:eu-repo/semantics/openAccess ca_ES
dc.type.version info:eu-repo/publishedVersion ca_ES
dc.indexacio Indexat a SCOPUS
dc.indexacio Indexat a WOS/JCR ca_ES

Files in this item

Show simple item record

Aquest document està subjecte a aquesta llicència Creative Commons Except where otherwise noted, this item's license is described as Aquest document està subjecte a aquesta llicència Creative Commons

Search RIUVic


Advanced Search

Browse

Statistics